BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C, a capability that could transform global outbreak response readiness. The company’s publication, titled ‘Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,’ outlines preclinical data showing that the company’s filovirus vaccine antigens, formulated with its proprietary ThermoVax(R) platform, maintained structural integrity and immunogenicity after 12 months of storage at 40°C. The same formulation also outperformed unstabilized comparators that degraded significantly under identical conditions. Most recently, this stability window was increased to at least 2 years (24 months) at 40°C. The publication expands earlier work funded through ongoing U.S. government contracts with BARDA and the National Institute of Allergy and Infectious Diseases.”

To view the full article, visit https://ibn.fm/EkiE7

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX